We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD).
A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the disease under control for 13 months including the discontinuation period.
Written by:
Utsunomiya N, Kono Y, Matsumoto K, Matsumoto T, Nakagawa A, Tsunemori H, Okada T, Muguruma K, Kawakita M. Are you the author?
The Department of Urology, Kobe City Medical Center General Hospital; The Department of Respiratory Medicine, Kobe City Medical Center General Hospital.
Reference: Hinyokika Kiyo. 2014 Jan;60(1):25-8.
PubMed Abstract
PMID: 24594769
Article in Japanese.
UroToday.com Renal Cancer Section
